Patel Sushil 4

What Happened
Sushil Patel, a director of Revolution Medicines (RVMD), was granted equity awards reported on June 18, 2026 and filed on Form 4 on June 23, 2026. The awards consist of 1,191 restricted stock units (RSUs) and a derivative award (an option) covering 3,127 shares. Both items show an acquisition price of $0.00 in the filing (award compensation, not an open‑market purchase or sale).

Key Details

• Transaction date(s): June 18, 2026; Form 4 filed June 23, 2026.
• Award types and amounts: 1,191 RSUs (non‑cash award) and an option for 3,127 shares (derivative). Reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 confirms the 1,191 units are RSUs. F2 states the option vests in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the next Annual Meeting, subject to the director remaining a service provider under the 2020 Plan.
• Filing timeliness: Form filed June 23, 2026 for a June 18 transaction; the filing itself shows the trade date and filing date but does not flag a late filing in the disclosure.

Context
These grants are compensation awards (code A) rather than purchases, so they reflect equity compensation and vesting conditions rather than an immediate vote of confidence via a market purchase. The option is not exercised now — it will vest per the schedule in F2 and only becomes exercisable/convertible according to the plan and continued service. Awards like RSUs typically convert to common stock at vesting and may be subject to transfer restrictions and tax withholding.